Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

NCT01154387 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

End Stage Renal Disease
Renal Transplant

Interventions

DRUG: Anti-Thymocyte Globulin
DRUG: TOL101
DRUG: TOL101
DRUG: Steroids
DRUG: Tacrolimus
DRUG: Mycophenolate mofetil (MMF)

Sponsor

Tolera Therapeutics, Inc